New method to prevent antibodies from blocking gene therapy delivery
Novel strategy to block Nabs for AAV gene delivery
This study is looking at a new way to make gene therapy work better for people who have antibodies that can block the treatment, by using a special protein that helps the therapy get through those barriers.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-11045091 on NIH RePORTER |
What this research studies
This research focuses on improving the delivery of gene therapy using adeno-associated virus (AAV) vectors by developing a novel strategy to block neutralizing antibodies (Nabs) that hinder their effectiveness. The approach involves using a unique protein, termed Protein-M, which can interact with antibodies without being dependent on specific antigens. This method aims to enhance the efficiency of AAV vectors in patients who have pre-existing antibodies, thereby potentially increasing the success of gene therapies for various disorders. The research will evaluate the effectiveness of this protein-based strategy in laboratory settings before considering clinical applications.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients who require gene therapy and have pre-existing neutralizing antibodies against AAV vectors.
Not a fit: Patients who do not require gene therapy or those without neutralizing antibodies against AAV vectors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve the effectiveness of gene therapies for patients with conditions currently treated with AAV vectors.
How similar studies have performed: Other research has shown promise in using similar strategies to evade neutralizing antibodies, but this specific approach with Protein-M is novel.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Li, Chengwen — Univ of North Carolina Chapel Hill
- Study coordinator: Li, Chengwen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.